Spurred by concerns about the “deny and defend” model — including its cost, lack of transparency and the perpetuation of errors — programs to circumvent litigation by offering prompt disclosure, apology and compensation for mistakes as an alternative to malpractice suits are becoming more popular.
In January, the city filed a first-of-its-kind lawsuit against Purdue Pharma alleging the drug maker “supplied OxyContin to obviously suspicious physicians and pharmacies,” ultimately failing “to prevent the illegal diversion of OxyContin into the black market.”
While other suits against the company by states and municipalities have accused Purdue Pharma of deceptive marketing — allegedly playing up OxyContin’s effectiveness while playing down its addictiveness — Everett’s lawsuit is the first to claim the company knew its drugs were being diverted and did nothing to stop it.
Scientists have taken another important step toward creating different types of synthetic life in the laboratory. An international research consortium reports Thursday that it has figured out an efficient method for synthesizing a substantial part of the genetic code of yeast.
Employers could impose hefty penalties on employees who decline to participate in genetic testing as part of workplace wellness programs if a bill approved by a U.S. House committee this week becomes law.
Deaths in West Virginia have overwhelmed a state program providing burial assistance for needy families for at least the fifth year in a row, causing the program to be nearly out of money four months before the end of the fiscal year, according to the state’s Department of Health and Human Resources (DHHR). Funeral directors in West Virginia say the state’s drug overdose epidemic, the worst in the nation, is partly to blame.
China’s central government is laying plans to curb pollution, increase food and drug safety, and boost scientific research—though supporting details are scarce.
Chinese Premier Li Keqiang outlined these and other major goals during the opening session of the National People’s Congress on Sunday. The congress discussions are not likely to result in new legislation specific to science but speeches by top leaders set the tone for policy over the coming year.
“Having reached the current stage of development, China can now advance only through reform and innovation,” Li said in support of his call to boost research efforts. China has “the largest pool of scientists, engineers, and professionals in the world, and their potential for innovation is truly tremendous.”
The Trump administration wants to cut spending by EPA’s Office of Research and Development (ORD) by more than 40% from roughly $510 million to $290 million, according to sources that have seen preliminary directives from the White House’s Office of Management and Budget (OMB). The cuts target scientific work in fields including climate change, air and water quality, and chemical safety. EPA’s $50 million external grant program for environmental scientists at universities would disappear altogether. Such erasures represent just part of a larger plan to shrink EPA’s budget by 25% to $6.1 billion.
Seventy years ago, on the day Wenceslaus and Denicia Billiot got married, their wedding party danced along a road that ran from one end of Isle de Jean Charles to the other.
Each year, environmental pollutants cost an estimated 1.7 million lives among children under 5, according to World Health Organization reports released Monday.
A meeting Friday afternoon between President Trump and Ohio Gov. John Kasich, his former rival in the GOP primaries, had no set agenda. But Kasich came armed with one anyway: his hope to blunt drastic changes to the nation’s health-care system envisioned by some conservatives in Washington.
Over the past few years, researchers have identified some of the machinery involved in regulating these marks. Each requires a writer to place it, an eraser to remove it and a reader to interpret it. As the identities of these proteins emerged, scientists have come to understand that m6A affects not only RNA splicing, but also translation and RNA stability.
Global funding for research on neglected diseases — which include tuberculosis, HIV/AIDS and malaria — is at its lowest level since 2007, according to the annual G-FINDER investment report by Policy Cures Research, a health-policy analysis firm in Sydney, Australia.
Yesterday, at a meeting here organized by the Smithsonian Initiative on Biodiversity Genomics and the Shenzhen, China–based sequencing powerhouse BGI, a small group of researchers upped the ante even more, announcing their intent to, eventually, sequence “all life on Earth.”
Overall, 23 of the scientists (roughly 8% of sanctioned researchers) received NIH funding after receiving an ORI sanction. Of that group, 17 researchers won more than $101 million for 61 new projects. Thirteen continued to receive funding from NIH grants that had been awarded before being sanctioned.
As the science grew even more compelling and venture capital (VC) beckoned, the jockeying to start CRISPR companies became intense. The research community was rent apart by concerns about intellectual property, academic credit, Nobel Prize dreams, geography, media coverage, egos, personal profit, and loyalty. A billion dollars poured into what might be called CRISPR Inc.
Rather than wait years for treatments to be approved by federal officials, many of them are testing ways to modify human biology that fall somewhere on the spectrum between science and entrepreneurialism. It’s called biohacking, and it’s one of the biggest things happening in the Bay Area.
Now, 22 teams of computer scientists have unveiled a set of algorithms able to predict the odor of different molecules based on their chemical structure. It remains to be seen how broadly useful such programs will be, but one hope is that such algorithms may help fragrancemakers and food producers design new odorants with precisely tailored scents.
The New York Times
The Broad Institute in Cambridge, Mass., will retain potentially lucrative rights to a powerful gene-editing technique that could lead to major advances in medicine and agriculture, the federal Patent and Trademark Office ruled on Wednesday.
An old steroid treatment, long available outside the United States, received approval this week for a rare disease that afflicts about 15,000 Americans. Though not previously approved in the United States, the drug, deflazacort, has for years been available to patients suffering from the devastating and fatal disease Duchenne muscular dystrophy; families can import it from abroad for about $1,200 per year on average. The new list price for the drug? $89,000 a year.
Los Angeles Times
As with Trump’s proposed elimination of consumer safeguards, environmental-protection measures and financial reforms, the reality is that if his administration proceeds with a wholesale deregulation of the drug industry, the public will be largely undefended against the aggressive and potentially dangerous predations of multibillion-dollar conglomerates.
France’s government auditor has taken a sharp swipe at efforts to develop a science super-campus near Paris that, by 2020, was supposed to rival the world’s top campus universities, such as the US Massachusetts Institute of Technology (MIT). More than €5.3 billion (US$5.7 billion) in public spending has been earmarked for the Paris-Saclay science cluster, the Court of Auditors estimates in an annual report published on 8 February — but the original vision of creating a large integrated research university there is “at a standstill”.
Price now takes the helm of a $1 trillion government department that includes the National Institutes of Health (NIH), the Centers for Disease Control and Prevention, and the Food and Drug Administration (FDA). Most visibly, he will be charged with overseeing the repeal and replacement of the Affordable Care Act, also known as Obamacare, that Republicans have promised.
A group backed by the Bill & Melinda Gates Foundation that works on India’s immunization program will now be funded by the health ministry, a government official said, a move in part prompted by fears foreign donors could influence policy making.
Legislators in Hawaii are trying to ban the sale of sunscreens that contain two UV-filtering chemicals, after studies suggested that they harm coral reefs.
The U.S. Department of Agriculture (USDA) today removed public access to tens of thousands of reports that document the numbers of animals kept by research labs, companies, zoos, circuses, and animal transporters—and whether those animals are being treated humanely under the Animal Welfare Act. Henceforth, those wanting access to the information will need to file a Freedom of Information Act request.
Los Angeles Times
Donald Trump will be coming into office waving the banner of deregulation. While most of the speculation about his plans has focused on the financial industry and the possibility of eviscerating Dodd-Frank reforms, keep your eyes on the Food and Drug Administration. In a Trump administration the agency, figuratively speaking, will have a big bull’s-eye on its back.
Some fear a demonstration led by researchers might only serve to paint scientists as an interest group, further politicizing scientific issues. And at least one veteran science lobbyist has urged organizers to make sure it’s a march for science, not scientists.
By studying the insects under more-natural conditions, scientists hope to better understand how to eradicate them — and malaria — using an emerging genetic-engineering technology called gene drives. The technique can quickly disseminate genetic modifications in wild populations through an organism’s offspring, prompting some activists to call for it to be shelved. Yet gene drives might not be as effective as activists think. Recent research has identified a major hurdle to using them to eliminate diseases and vanquish invasive pests: evolution.